In a $5.4 billion deal, Pfizer fully acquired Global Blood Therapeutics (GBT), bolstering its decades-long standing in the field of rare blood disorders, particularly regarding sickle cell disease (SCD). With the newly completed acquisition — plans were announced in August — Pfizer gains GBT’s therapy portfolio and pipeline.

In a move to enhance three decades of treatment development in rare hematology, Pfizer will acquire Global Blood Therapeutics (GBT), a biopharmaceutical company that has been a leader in sickle cell disease (SCD) therapeutics, for $5.4 billion. The acquisition brings GBT’s treatment portfolio and pipeline — and its…

The U.S. Food and Drug Administration (FDA) has granted both orphan drug and rare pediatric disease designations to inclacumab and GBT601, two experimental therapies for sickle cell disease (SCD) being developed by Global Blood Therapeutics (GBT). These designations confer benefits to therapy developers that are designed to speed…

GBT601 and inclacumab, experimental therapies from Global Blood Therapeutics (GBT) for sickle cell disease (SCD) and associated vaso-occlusive crises (VOCs), were generally safe and showed signs of biological activity in healthy volunteers, according to data from Phase 1 clinical trials. These findings will be presented by GBT through two…

Children with sickle cell disease (SCD) as young as age 4 could be prescribed Oxbryta (voxelotor) if the U.S. Food and Drug Administration approves a supplemental new drug application (sNDA) submitted by the therapy’s developers. Global Blood Therapeutics (GBT) is asking the FDA to expand the use of…

Global Blood Therapeutics (GBT) is currently focused on expanding the use of Oxbryta (voxelotor) to children, ages 4–11, with sickle cell disease (SCD). But research into its use with younger children, as well as studies into other potential SCD therapies, are also underway. “Sickle cell disease patients of all ages worldwide…

Hoffmann-La Roche has sold the worldwide rights to its discontinued heart disease drug, inclacumab, to Global Blood Therapeutics (GBT) for $2 million and milestone payments. GBT plans to investigate inclacumab as a treatment for painful blockages of blood vessels in patients with sickle cell disease (SCD). The technology transfer process…